Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy
Hye Jin Jin,Yun Kyung Bae,Mi-Yeon Kim,Soon-Jae Kwon,Hong Bae Jeon,Soo Jin Choi,Seong Who Kim,Yoon Sun Yang,Wonil Oh,Jong Wook Chang +9 more
607
TL;DR: It is found that recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA) was responsible for this beneficial effect in part by preventing inflammation.
read more
Abstract: Various source-derived mesenchymal stem cells (MSCs) have been considered for cell therapeutics in incurable diseases. To characterize MSCs from different sources, we compared human bone marrow (BM), adipose tissue (AT), and umbilical cord blood-derived MSCs (UCB-MSCs) for surface antigen expression, differentiation ability, proliferation capacity, clonality, tolerance for aging, and paracrine activity. Although MSCs from different tissues have similar levels of surface antigen expression, immunosuppressive activity, and differentiation ability, UCB-MSCs had the highest rate of cell proliferation and clonality, and significantly lower expression of p53, p21, and p16, well known markers of senescence. Since paracrine action is the main action of MSCs, we examined the anti-inflammatory activity of each MSC under lipopolysaccharide (LPS)-induced inflammation. Co-culture of UCB-MSCs with LPS-treated rat alveolar macrophage, reduced expression of inflammatory cytokines including interleukin-1α (IL-1α), IL-6, and IL-8 via angiopoietin-1 (Ang-1). Using recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA), we found that Ang-1 secretion was responsible for this beneficial effect in part by preventing inflammation. Our results demonstrate that primitive UCB-MSCs have biological advantages in comparison to adult sources, making UCB-MSCs a useful model for clinical applications of cell therapy.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine.
Soudeh Moghadasi,Marischa Elveny,Heshu Sulaiman Rahman,Heshu Sulaiman Rahman,Wanich Suksatan,Abduladheem Turki Jalil,Walid Kamal Abdelbasset,Walid Kamal Abdelbasset,Alexei Valerievich Yumashev,Siavash Shariatzadeh,Roza Motavalli,Farahnaz Behzad,Faroogh Marofi,Ali Hassanzadeh,Yashwant Pathak,Mostafa Jarahian +15 more
TL;DR: In this article, mesenchymal stem/stromal cells (MSCs) exosomes are used to convey functional molecules such as long non-coding RNAs (lncRNAs) and micro-RNAs (miRNAs), proteins (e.g., chemokine and cytokine), and lipids from MSCs to target cells.
Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer.
TL;DR: Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.
Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential.
Vladislav Volarevic,Marina Gazdic,Bojana Simovic Markovic,Nemanja Jovicic,Valentin Djonov,Nebojsa Arsenijevic +5 more
TL;DR: Current findings regarding immuno‐modulatory effects of MSC‐derived factors are emphasized and their potential in the therapy of immune‐mediated diseases is emphasized.
166
A Brief Overview of Global Trends in MSC-Based Cell Therapy
Dragomirka Jovic,Yingjia Yu,Dan Wang,Kuixing Wang,Hanbo Li,Fengping Xu,Junnian Liu,Yonglun Luo +7 more
TL;DR: In this paper , a comprehensive review of reported data of mesenchymal stem cells clinical trials conducted globally is presented, highlighting therapeutic effects of MSCs in several representative diseases, including neurological, musculoskeletal diseases and most recent Coronavirus infectious disease.
Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6
Sushma Chaubey,Sam Thueson,Devasena Ponnalagu,Mohammad Afaque Alam,Ciprian P. Gheorghe,Zubair H. Aghai,Harpreet Singh,Vineet Bhandari +7 more
TL;DR: Preterm hUC-derived MSC-CM EXO alleviates hyperoxia-induced BPD and its associated pathologies, in part, via exosomal factor TSG-6, an immunomodulatory glycoprotein, in EXO.
References
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Massimo Dominici,K. Le Blanc,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Diane S. Krause,Robert J. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz +9 more
TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
17.5K
Pluripotency of mesenchymal stem cells derived from adult marrow
Yuehua Jiang,Balkrishna N. Jahagirdar,R. Lee Reinhardt,Robert E. Schwartz,C. Dirk Keene,Xilma R. Ortiz-Gonzalez,Morayma Reyes,Todd Lenvik,Troy C. Lund,Mark Blackstad,Jingbo Du,Sara Aldrich,Aaron Lisberg,Walter C. Low,David A. Largaespada,Catherine M. Verfaillie +15 more
TL;DR: It is reported here that cells co-purifying with mesenchymal stem cells—termed here multipotent adult progenitor cells or MAPCs—differentiate, at the single cell level, not only into meschymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro.
Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.
TL;DR: Both UCB and AT are attractive alternatives to BM in isolating MSC: AT as it contains MSCs at the highest frequency and UCB as it seems to be expandable to higher numbers.
3.5K
Mesenchymal stem cells as trophic mediators.
Arnold I. Caplan,James E. Dennis +1 more
TL;DR: Several studies which tested the use of MSCs in models of infarct (injured heart), stroke (brain), or meniscus regeneration models are reviewed within the context of M SC‐mediated trophic effects in tissue repair.
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine.
TL;DR: The biological basis for the in vivo functioning of MSCs through development and aging is summarized and they appear to be valuable mediators for tissue repair and regeneration.
2K